PMID- 28984477
OWN - NLM
STAT- MEDLINE
DCOM- 20171117
LR  - 20171128
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 16
IP  - 12
DP  - 2017 Dec
TI  - Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD.
PG  - 1335-1345
LID - 10.1080/14740338.2017.1389894 [doi]
AB  - Attention-deficit hyperactivity disorder (ADHD) is a common neurobehavioral 
      disorder in children and adolescents that comprises core symptoms of 
      developmentally inappropriate levels of inattention and/or hyperactivity and 
      impulsivity. Stimulant (methylphenidate, amphetamines) and non stimulant 
      (atomoxetine, clonidine and guanfacine) are the treatment usually prescribed for 
      ADHD. Area covered: This review covers the safety of ADHD medications in children 
      and adolescents. MEDLINE, EMBASE and PsycINFO databases were searched with the 
      aim to retrieve prospective studies that monitored the incidence of adverse 
      events (AEs) in children receiving drug therapy for ADHD. Many of the studies 
      investigated the risk of specific AEs. In particular, the cardiovascular safety, 
      the impact on growth and on sleep pattern, the risk of substance use disorders 
      and of suicidal ideation are among the topics more studied. Expert opinion: 
      Effective drugs for ADHD appears to be safe and well tolerated. Most of the 
      adverse events reported in the randomised controlled trials are mild and 
      transient. Decreased appetite, growth decrease and the impact on sleep (insomnia 
      for stimulants and somnolence for alpha2-agonists) are among the most common 
      events. Concerns exist about cardiovascular and psychiatric AEs, even if the 
      available evidence does not support an association with medications.
FAU - Clavenna, Antonio
AU  - Clavenna A
AUID- ORCID: 0000-0001-5536-4192
AD  - a Laboratory for Mother and Child Health, Department of Public Health , IRCCS - 
      Istituto di Ricerche Farmacologiche "Mario Negri" , Milan , Italy.
FAU - Bonati, Maurizio
AU  - Bonati M
AD  - a Laboratory for Mother and Child Health, Department of Public Health , IRCCS - 
      Istituto di Ricerche Farmacologiche "Mario Negri" , Milan , Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171012
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Central Nervous System Stimulants)
SB  - IM
MH  - Adolescent
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy
MH  - Central Nervous System Stimulants/*administration & dosage/adverse effects
MH  - Child
MH  - Drug-Related Side Effects and Adverse Reactions/epidemiology
MH  - Humans
MH  - *Pharmacoepidemiology
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Amphetamines
OT  - atomoxetine
OT  - attention deficit hyperactivity disorder
OT  - drug-related side effects and adverse reactions
OT  - methylphenidate
OT  - pediatrics
EDAT- 2017/10/07 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/10/07 06:00
PHST- 2017/10/07 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/10/07 06:00 [entrez]
AID - 10.1080/14740338.2017.1389894 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2017 Dec;16(12):1335-1345. doi: 
      10.1080/14740338.2017.1389894. Epub 2017 Oct 12.